CNS Pharmaceuticals Inc. (CNSP)
CNS Pharmaceuticals Statistics
Share Statistics
CNS Pharmaceuticals has 2.94M shares outstanding. The number of shares has increased by 0.2% in one year.
| Shares Outstanding | 2.94M |
| Shares Change (YoY) | 0.2% |
| Shares Change (QoQ) | 30.66% |
| Owned by Institutions (%) | 3.2% |
| Shares Floating | 2.92M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 338.69K, so 11.5% of the outstanding shares have been sold short.
| Short Interest | 338.69K |
| Short % of Shares Out | 11.5% |
| Short % of Float | 11.5% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.15 and the forward PE ratio is -0.21. CNS Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.15 |
| Forward PE | -0.21 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/FCF Ratio | -0.13 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CNS Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.43 |
| Quick Ratio | 3.43 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 924.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.71M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.08, so CNS Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 9.23 |
| Relative Strength Index (RSI) | 36.68 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.9M |
| Net Income | -14.86M |
| EBITDA | -14.9M |
| EBIT | -14.87M |
| Earnings Per Share (EPS) | -38.87 |
Balance Sheet
The company has 6.46M in cash and 326.07K in debt, giving a net cash position of 6.14M.
| Cash & Cash Equivalents | 6.46M |
| Total Debt | 326.07K |
| Net Cash | 6.14M |
| Retained Earnings | -84.42M |
| Total Assets | 8.7M |
| Working Capital | 6.13M |
Cash Flow
In the last 12 months, operating cash flow was -17.11M and capital expenditures -4.19K, giving a free cash flow of -17.12M.
| Operating Cash Flow | -17.11M |
| Capital Expenditures | -4.19K |
| Free Cash Flow | -17.12M |
| FCF Per Share | -44.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNSP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CNSP.
| Price Target | $25 |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Feb 21, 2025. It was a backward split with a ratio of 1:50.
| Last Split Date | Feb 21, 2025 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -17.73 |
| Piotroski F-Score | 2 |